Cross AS - Search Results

1

Correction to: Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate.

Oyler BL, Khan MM, Smith DF, Harberts EM, Kilgour DPA, Ernst RK, Cross AS, Goodlett DR. Oyler BL, et al. Among authors: cross as. J Am Soc Mass Spectrom. 2018 Jun;29(6):1230. doi: 10.1007/s13361-018-1960-8. J Am Soc Mass Spectrom. 2018. PMID: 29687418

2

Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate.

Oyler BL, Khan MM, Smith DF, Harberts EM, Kilgour DPA, Ernst RK, Cross AS, Goodlett DR. Oyler BL, et al. Among authors: cross as. J Am Soc Mass Spectrom. 2018 Jun;29(6):1221-1229. doi: 10.1007/s13361-018-1897-y. Epub 2018 Feb 20. J Am Soc Mass Spectrom. 2018. PMID: 29464544 Free PMC article.

3

A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis.

Cross AS, Opal SM, Palardy JE, Shridhar S, Baliban SM, Scott AJ, Chahin AB, Ernst RK. Cross AS, et al. Innate Immun. 2021 Apr;27(3):266-274. doi: 10.1177/17534259211007538. Innate Immun. 2021. PMID: 33858243 Free PMC article.

4

Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.

Cross AS, Opal S, Cook P, Drabick J, Bhattacharjee A. Cross AS, et al. Vaccine. 2004 Feb 17;22(7):812-7. doi: 10.1016/j.vaccine.2003.11.025. Vaccine. 2004. PMID: 15040932 Review.

5

Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

Cross AS, Opal SM, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattacharjee AK. Cross AS, et al. Vaccine. 2003 Nov 7;21(31):4576-87. doi: 10.1016/s0264-410x(03)00483-3. Vaccine. 2003. PMID: 14575770 Clinical Trial.

6

Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors.

Chen WH, Basu S, Bhattacharjee AK, Cross AS. Chen WH, et al. Among authors: cross as. Innate Immun. 2010 Oct;16(5):322-32. doi: 10.1177/1753425909346973. Epub 2009 Oct 12. Innate Immun. 2010. PMID: 19822632 Free PMC article.

7

Development of an anti-endotoxin vaccine for sepsis.

Cross AS. Cross AS. Subcell Biochem. 2010;53:285-302. doi: 10.1007/978-90-481-9078-2_13. Subcell Biochem. 2010. PMID: 20593272

8

Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.

Cross AS. Cross AS. Microbiol Mol Biol Rev. 2023 Sep 26;87(3):e0004522. doi: 10.1128/mmbr.00045-22. Epub 2023 Jul 11. Microbiol Mol Biol Rev. 2023. PMID: 37432116 Free PMC article. Review.

9

Klebsiella pneumoniae Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease.

Miller JC, Cross AS, Tennant SM, Baliban SM. Miller JC, et al. Among authors: cross as. Vaccines (Basel). 2024 Oct 17;12(10):1177. doi: 10.3390/vaccines12101177. Vaccines (Basel). 2024. PMID: 39460343 Free PMC article. Review.

10

Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.

Cross AS, Opal SM, Warren HS, Palardy JE, Glaser K, Parejo NA, Bhattacharjee AK. Cross AS, et al. J Infect Dis. 2001 Apr 1;183(7):1079-86. doi: 10.1086/319297. Epub 2001 Mar 8. J Infect Dis. 2001. PMID: 11237833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters